SCHEMBL1966223

SCHEMBL1966223

CC(C)(C)OC(=O)N(Cc1cccc(C(F)(F)F)c1)n1cccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
GFER P55789 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAOB P27338 2/20 0.41
CETP P11597 2/20 0.41
ACP3 P15309 1/20 0.40
SERPINE1 P05121 1/20 0.40
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
NR4A2 P43354 1/20 0.39
PRKCA P17252 1/20 0.39
PRKCD Q05655 1/20 0.39
EPHX1 P07099 1/20 0.39
PTGES O14684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1966228 0.86 MEN1 (0.41) ALDH1A1MEN1KMT2AMAOBKDM4E
SCHEMBL1965544 0.85 RIPK1 (0.47) ALDH1A1GFERMEN1KMT2AMAOB
SCHEMBL1965890 0.83 RIPK1 (0.47) KMT2AMAOBKDM4ESMN1; SMN2L3MBTL1
SCHEMBL1964950 0.82 AKT1 (0.46) MEN1KMT2AL3MBTL1
SCHEMBL5142910 0.80 MEN1 (0.45) ALDH1A1HDAC6MEN1KMT2AMAOB
SCHEMBL1966131 0.79 KDM1A (0.42) HDAC6MEN1KMT2A
SCHEMBL1965084 0.78 CTSB (0.40) MEN1KMT2A
SCHEMBL1964559 0.77 LMNA (0.44) ALDH1A1MAOBKDM4EGAA
SCHEMBL2257957 0.76 TAAR1 (0.46) ALDH1A1HDAC6MEN1KMT2AMAOB
SCHEMBL1965415 0.76 GPR119 (0.36) ALDH1A1KDM4ESMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 ALDH1A1 268/4885GFER 2812/4885HDAC6 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.